Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug
Twelve years ago, Takeda became the first major Asian pharma company to buy into Alnylam’s pioneering RNAi platform with a landmark $1 billion alliance. Two …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
